Merck (MRK) said Thursday that it has initiated a pivotal phase 3 clinical trial evaluating zilovertamab vedotin, an investigational antibody-drug conjugate to treat patients with previously untreated diffuse large B-cell lymphoma.
The company said the trial will combine zilovertamab vedotin with rituximab plus cyclophosphamide, doxorubicin and prednisone, compared with rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone.
Merck said patient enrollment for the trial has already begun.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.